Abstract:Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the western countries. The histological spectrum of NAFLD includes simple steatosis, steatohepatitis, fibrosis, cirrhosis and even hepatocellular carcinoma. Nuclear receptors are a large group of ligand-dependent transcription factors that sense the environmental and endogenous changes and regulate numerous physiological and pathological processes. Accumulating evidence has suggested that a dysregulation of nuclear receptors in NAFLD may effect on the metabolism of endogenous and exogenous chemicals in the liver. The current study was designed to systematically characterize the time-dependent modulation of nuclear receptors including the peroxisome proliferator-activated receptors (PPARs), the constitutive androstane receptor (CAR), the pregnane X receptor (PXR), the liver X receptor (LXR), and the farnesoid X receptor (FXR) in the progression of NAFLD. Male C57BL/6 mice fed by a high fat diet were used to induce NAFLD. Hepatic steatosis, lobular inflammation, progressive fibrosis, increased hepatocyte DNA synthesis, and liver tumor formation were observed at various time points in our mouse model. During the development of hepatic steatosis (8-16 weeks), PPARα was activated as indicated by its target genes as well as the elevated peroxisomal acyl-CoA oxidase activity. The mRNA level of Pparγ was also upregulated while Pparδ gene expression was significantly reduced during the development of hepatic steatosis. PXR target gene Cyp3a11 was consistently increased 3-4-fold in addition to the increased microsomal Cyp3a enzymatic activity at all stages of NAFLD. In contrast, CAR mediated Cyp2b10 gene expression was found increased only by week 12. LXRα target genes Abcg5 and Abcg8 were significantly elevated during the whole course of NAFLD. The mRNA of Fxr was downregulated at 24 and 32 weeks in high fat diet fed mice, which might correlate with the development of progressive fibrosis at the stage of steatohepatitis. The results of our study provided a systematic evaluation of the changes of nuclear receptors and their downstream chemicalmetabolism and transport enzymes in the progression of NAFLD.

Effects of riboflavin deficiency and high dietary fat on hepatic lipid accumulation: a synergetic action in the development of non-alcoholic fatty liver disease

Vitamin D Receptor Targets Hepatocyte Nuclear Factor 4α and Mediates Protective Effects of Vitamin D in Nonalcoholic Fatty Liver Disease.

Riboflavin Ameliorates Mitochondrial Dysfunction Via the AMPK/PGC1α/HO‑1 Signaling Pathway and Attenuates Carbon Tetrachloride‑induced Liver Fibrosis in Rats.

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.

Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease

Lipotoxic Effect of P21 on Free Fatty Acid-Induced Steatosis in L02 Cells

Iron overload accelerated lipid metabolism disorder and liver injury in rats with non-alcoholic fatty liver disease

Severe riboflavin deficiency induces alterations in the hepatic proteome of starter Pekin ducks

Vitamin E and Nonalcoholic Fatty Liver Disease (Nafld)

Effects of Flavonoids on Alcoholic Liver Disease: A Review

Non‐alcoholic Fatty Liver Disease: Beneficial Effects of Flavonoids

Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease

Multi-Omics Characterizes the Effects and Mechanisms of CD1d in Nonalcoholic Fatty Liver Disease Development

Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease

Impaired Hepatic Vitamin A Metabolism in NAFLD Mice Leading to Vitamin A Accumulation in Hepatocytes

The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD

Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease

Study on the mechanism of vitamin E alleviating non-alcoholic fatty liver function based on non-targeted metabolomics analysis in rats

Riboflavin ameliorates pathological cardiac hypertrophy and fibrosis through the activation of short-chain acyl-CoA dehydrogenase

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease